AstraZeneca is gearing up to present a wealth of new clinical, real-world, and early science data encompassing its Vaccines & Immune Therapies portfolio at the 34th European Congress of Clinical…
Alert Overview This alert from the World Health Organization (WHO) addresses the discovery of falsified DOW USP/EP Propylene Glycol in Pakistan. Authentic DOW USP/EP Propylene Glycol is a crucial raw…
Viatris, a leading global healthcare company, has announced the appointment of Corinne Le Goff as its Chief Commercial Officer, effective immediately. Le Goff brings over 25 years of experience in…
WuXi Biologics, known as WuXi Bio (2269.HK), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), proudly announces its selection for the prestigious S&P Global Sustainability Yearbook 2024 (“Yearbook”)…
Labcorp, a leading provider of innovative laboratory services globally, has announced the launch of the nation’s inaugural glial fibrillary acidic protein (GFAP) test. This test serves as a pivotal blood-based…
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) has received FDA approval for TEVIMBRA® (tislelizumab-jsgr) as a monotherapy for adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC)…
Novartis recently shared promising findings from the Phase III APPLAUSE-IgAN study of Fabhalta® (iptacopan), a Factor B inhibitor targeting the alternative complement pathway, in patients with IgA nephropathy (IgAN). In…
A recent modeling analysis conducted by AstraZeneca, named IMPACT CKD, projects that by 2032, up to 16.5% of the population across eight countries will be afflicted by chronic kidney disease…
Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) announced that it has entered into an agreement with Ginkgo Bioworks (Ginkgo) to join the Ginkgo Technology Network. This strategic alliance will enable…
Agenus Inc. (NASDAQ: AGEN), a renowned player in the realm of discovering and advancing novel immunological treatments for diverse cancers, has disclosed the latest outcomes from its Phase 1 clinical…
Revance Therapeutics, Inc. (NASDAQ: RVNC) has unveiled significant insights into DAXXIFY® for the treatment of cervical dystonia at the American Academy of Neurology (AAN) annual meeting, running from April 13-18,…
Introducing the latest addition to ResearchAndMarkets.com’s offerings, the report on the “Global Dermal Fillers Market, 2023-2035”. Estimated at $3 billion in 2023, the global dermal fillers market is poised for…